Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2032

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Epirubicin.

DRUG

Epirubicin

Epirubicin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Cyclophosphamide.

DRUG

Docetaxel

Docetaxel is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Carboplatin. Dosing will start after treatment with Epirubicin and Cyclophosphamide (EC) is completed.

DRUG

Carboplatin

Carboplatin is given by intravenous (IV) infusion once every 3 weeks for 4 doses total (12 weeks). It will be given together with Docetaxel. Dosing will start after treatment with EC is completed.

PROCEDURE

Breast Surgery

Participants will undergo breast surgery after completing dosing with Carboplatin and Docetaxel to remove any remaining cancer in the breast.

DRUG

Capecitabine

Capecitabine is a pill that will be taken by mouth daily for 6 months after surgery is completed.

Trial Locations (4)

100254

Lagos University Teaching Hospital, Yaba

100271

Lagos State University Teaching Hospital, Ikeja

200285

University of Ibadan Hospital, Ibadan

220005

Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife

All Listed Sponsors
lead

University of Chicago

OTHER